Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE)
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of the combination of Anlotinib
wiht Toripalimab in advanced gastric or gastro-oesophageal junction cancer as first-line
treatment.